| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 02/16/2010 | US7662399 BASB054 polypeptides |
| 02/16/2010 | US7662398 Microorganisms for therapy |
| 02/16/2010 | US7662397 Major nucleocapsid protein/phosphoprotein, large polymerase protein, a M2 (ORF1) RNA polymerase elongation factor, and RSV genome/antigenome of human strains; point mutations; glycoproteins; immunogens |
| 02/16/2010 | US7662396 Fusion protein of a self-antigen with a Listerial truncated ActA protein; use in genetic vaccines and vaccines against tumors such as Her-2-transformed tumor |
| 02/16/2010 | US7662395 Recombinant virus encoding an antigen of a disease state; second recombinant virus encoding an immunostimulatory molecule with an exogenous immunostimulatory molecule, chemotherapeutic drug, antibiotic, antiviral drug or antifungal drug. |
| 02/16/2010 | US7662394 Nucleic acids encoding chimeric Flavivirus immunogens comprising the Japanese encephalitis virus (JEV) PRM signal sequence |
| 02/16/2010 | US7662392 Stromal-Derived Factor-1 (SDF), G-CSF (granulocyte-colony stimulating factor), stimulating vasculogenesis; improves cardiac function |
| 02/16/2010 | US7662391 Polynucleotide sequence for Chalmydia pneumonia; therapy, prevention of Chlamydia infections ; vaccines |
| 02/16/2010 | US7662390 purified Lawsonia intracellularis protein for the detection of antibodies against Lawsonia intracellularis in animals ( pigs) for inducing protective immunity ; drug screening; Porcine proliferative enteropathy; gramnegative bacteria |
| 02/16/2010 | US7662389 Use of serum amyloid A gene in diagnosis and treatment of glaucoma and identification of anti-glaucoma agents |
| 02/16/2010 | US7662388 Endogenous peptide and active subfragments thereof |
| 02/16/2010 | US7662387 administering a conjugate of antibody ( humanized, chimeric or constant region) and a drug such as fetoprotein/alpha-/, monomethyl auristatin E or monomethyl auristatin F to treat CD70-expressing cancer selected from a kidney tumor, a B cell lymphoma, a thymic carcinoma, and a nasopharyngeal carcinoma |
| 02/16/2010 | US7662385 Agent for inhibiting proliferation of neural stem cells |
| 02/16/2010 | US7662384 Use of anti-α5β1 antibodies to inhibit cancer cell proliferation |
| 02/16/2010 | US7662383 Epitope bound by MAbs A, B, C or D, where MAbs A, B, C and D have given variable domains; chimeric or humanized for side effect reduction; polymerase chain reaction |
| 02/16/2010 | US7662382 Inducible ligand for α1β1 integrin and uses |
| 02/16/2010 | US7662381 isolated human monoclonal antibodies or antigen binding portion, that bind to IFNAR-1, capable of blocking the action of type I interferons; use in the treatment of immune mediated disorders, including autoimmune disorders, transplant rejection and Graft Versus Host Disease (GVHD) |
| 02/16/2010 | US7662380 ZAQ ligand-1 antibodies and uses thereof |
| 02/16/2010 | US7662379 Interleukin-10 antibodies |
| 02/16/2010 | US7662378 administering anti-CEA (carcinogenicembryonic antigen) monoclonal antibody (MAb) or fragment and a drug selected from vincristine, doxorubicin, dacarbazine (DTIC), cyclophosphamide, CPT-11, oxaliplatin, gemcitabine and 5-fluorouracil/leucovorin |
| 02/16/2010 | US7662377 Antigen binding molecules that bind EGFR, vectors encoding same, and uses thereof |
| 02/16/2010 | US7662376 sterol transporter polypeptide for use in the treatment of hypercholesterolemia, hyperlipidemia, gall stones, and atherosclerosis; monoclonal or polyclonal antibody or fab or fv fragments that specifically binds the polypeptide having specific amino acid sequence |
| 02/16/2010 | US7662375 Use of glucose-6-phosphate isomerase and antibodies thereto for the diagnosis and therapy of arthritis, and test of anti-arthritic compounds |
| 02/16/2010 | US7662374 Dual-specificity antibody having specificity for both an activated erbB2 receptor and erbB1 dimers, without significant affinity for monomeric EGFr that is not activate; specificity of the antibodies is due to their recognition and binding of activation epitopes; diagnosis, imaging and for treating tumor |
| 02/16/2010 | US7662371 Composition for lowering the concentration of intestinal pathogenic peptides |
| 02/16/2010 | CA2382602C Oligosaccharides derivatives of ribose-ribitol-phosphate and vaccines containing them |
| 02/16/2010 | CA2224444C Type f botulinum toxin and use thereof |
| 02/16/2010 | CA2223701C Fgf9 as a specific ligand for fgfr3 |
| 02/16/2010 | CA2177612C Nucleic acids encoding a house dust mite allergen, der p iii, and uses therefor |
| 02/11/2010 | WO2010017514A2 Methods of predicting cancer lethality using replikin counts |
| 02/11/2010 | WO2010017468A1 Treatment of autoimmune and inflammatory disease |
| 02/11/2010 | WO2010017443A2 Anti-beta-2-microglobulin agents and the use thereof |
| 02/11/2010 | WO2010017440A1 Infectious bronchitis vaccines derived from ib-qx-like strains |
| 02/11/2010 | WO2010017330A1 Microparticles for use in immunogenic compositions |
| 02/11/2010 | WO2010017248A2 Sting (stimulator of interferon genes), a regulator of innate immune responses |
| 02/11/2010 | WO2010017209A2 Membrane proximal region of hiv gp41 anchored to the lipid layer of a virus-like particle vaccine |
| 02/11/2010 | WO2010017196A2 Monoclonal antibodies against tissue factor pathway inhibitor (tfpi) |
| 02/11/2010 | WO2010017152A2 Modulation of toll-like receptor 8 expression by antisense oligonucleotides |
| 02/11/2010 | WO2010017103A2 Fully human anti-human nkg2d monoclonal antibodies |
| 02/11/2010 | WO2010017086A1 Effectors of par-2 activation and their use in the modulation of inflammation |
| 02/11/2010 | WO2010017083A1 Methods of treating cancer with cd11b antibodies |
| 02/11/2010 | WO2010017070A1 Anti-hepcidin-25 selective antibodies and uses thereof |
| 02/11/2010 | WO2010016912A2 Immunotherapeutic compositions for the treatment of alzheimer's disease |
| 02/11/2010 | WO2010016901A1 Compositions of activated botulinum holotoxin type b (150 kd) |
| 02/11/2010 | WO2010016895A1 Compositions of activated botulinum toxin type b |
| 02/11/2010 | WO2010016806A1 Vhz for diagnosis and treatment of cancers |
| 02/11/2010 | WO2010016760A2 Immunogenic composition for the treatment of bacterial infection |
| 02/11/2010 | WO2010016652A1 Antibody modulating the differentiation and function of dendritic cells via binding intercellular adhesion molecule-1 and use thereof |
| 02/11/2010 | WO2010016590A1 Therapeutic or prophylactic agent for generalized pain syndrome |
| 02/11/2010 | WO2010016526A1 Pharmaceutical composition for treatment and prevention of cancer |
| 02/11/2010 | WO2010015834A1 Antibodies specific for misfolded proteins and methods for their production |
| 02/11/2010 | WO2010015704A1 Pharmaceutical compositions comprising antibodies binding to ebv (epstein-barr virus) protein barf1 |
| 02/11/2010 | WO2010015701A1 Improved bacterial polysaccharide-polypeptide conjugate compositions |
| 02/11/2010 | WO2010015675A1 Process for the preparation of nicotine-based haptens |
| 02/11/2010 | WO2010015608A1 Compositions and methods for antibodies targeting complement protein c5 |
| 02/11/2010 | WO2010015090A1 Functionalized pyrrolidines and use thereof as iap inhibitors |
| 02/11/2010 | WO2010015032A1 Methods of treating and preventing glucose toxicity |
| 02/11/2010 | WO2010015022A1 Antigen-presenting scaffolds |
| 02/11/2010 | WO2009153518A3 Novel fusion proteins and use thereof for preparing hepatitis c vaccines |
| 02/11/2010 | WO2009134401A9 Methods of inhibiting infection by diverse subtypes of drug-resistant hiv-1 |
| 02/11/2010 | WO2009003125A8 Intravaginal drug delivery devices for the delivery of macromolecules and water-soluble drugs |
| 02/11/2010 | WO2009001219A9 Immunocytokines for cancer treatment in combination with chemotherapeutic agents |
| 02/11/2010 | US20100036084 Biodegradable poly(beta-amino esters) and uses thereof |
| 02/11/2010 | US20100035975 Methods of preventing and treating respiratory viral infection using immunomodulatory polynucleotide sequences |
| 02/11/2010 | US20100035842 Amino alcohol compounds or phosphonic acid derivatives thereof |
| 02/11/2010 | US20100035237 Novel antigen constructs useful in the detection and differentiation of antibodies to hiv |
| 02/11/2010 | US20100034875 Immunogenic compositions and methods of use |
| 02/11/2010 | US20100034855 Compositions For Eliciting An Immune Response Against Mycobacterium Avium Subspecies Paratuberculosis |
| 02/11/2010 | US20100034854 Compositions of activated botulinum holotoxin type B (150 KD) |
| 02/11/2010 | US20100034853 Compositions of activated botulinum toxin type B |
| 02/11/2010 | US20100034852 Methods and compositions for predicting and treating drug resistant strains of influenza virus |
| 02/11/2010 | US20100034851 AIDS Vaccine Based on Replicative Vaccinia Virus Vector |
| 02/11/2010 | US20100034850 Vaccine |
| 02/11/2010 | US20100034849 Recombinant Bicistronic Flavivirus Vectors |
| 02/11/2010 | US20100034848 Prevention of allergic sensitization |
| 02/11/2010 | US20100034847 Multiple vaccination including Serogroup C Meningococcus |
| 02/11/2010 | US20100034846 Novel method for treating h.pylori infections |
| 02/11/2010 | US20100034845 Hepatitis virus for use in the diagnosis and prevention of viral diseases in birds and humans; polynucleotide consisting of the nucleotide sequence of the ORF2 gene of an avian hepatitis E virus or its complementary strand |
| 02/11/2010 | US20100034844 Activation of HCV Specefic T Cells |
| 02/11/2010 | US20100034843 Immunogenic compositions and vaccines for ebola |
| 02/11/2010 | US20100034842 Compositions Employing Alternative Reading Frame Polypeptides for the Treatment of Cancer and Infectious Disease |
| 02/11/2010 | US20100034841 Antigenic polypeptide usable as therapeutic agent for malignant neoplasm |
| 02/11/2010 | US20100034840 Compositions and methods for eliciting an immune response to escape mutants of targeted therapies |
| 02/11/2010 | US20100034839 Methods for treating viral disorders |
| 02/11/2010 | US20100034838 Transdermal Administration of Active Agents for Systemic Effect |
| 02/11/2010 | US20100034837 Anthracycline derivative conjugates, process for their preparation and their use as antitumor compounds |
| 02/11/2010 | US20100034836 Compositions and methods for the diagnosis and alleviation of tumor |
| 02/11/2010 | US20100034835 Use of inhibitors of leukotriene b4 receptor blt2 for treating asthma |
| 02/11/2010 | US20100034834 Modified t cell receptors and related materials and methods |
| 02/11/2010 | US20100034833 High affinity human antibodies to human il-18 receptor |
| 02/11/2010 | US20100034832 Methods for manipulating stem cells |
| 02/11/2010 | US20100034831 Agents that Bind a Target in Pulmonary Tissue for Targeting Respiratory Diseases |
| 02/11/2010 | US20100034830 Rabies vaccine |
| 02/11/2010 | US20100034829 Liquid anti-rabies antibody formulations |
| 02/11/2010 | US20100034828 Method of Increasing Radiation Sensitivity by Inhibition of Beta One Integrin |
| 02/11/2010 | US20100034827 Novel hiv reverse transcriptase inhibitors |
| 02/11/2010 | US20100034826 Human monoclonal antibodies to protein tyrosine kinase 7 (ptk7) and methods for using anti-ptk7 antibodies |
| 02/11/2010 | US20100034825 Generation of a cancer-specific immune response toward muc1 and cancer specific muc1 antibodies |
| 02/11/2010 | US20100034824 Targeted biocides |
| 02/11/2010 | US20100034823 Crystalline anti-hTNFalpha antibodies |